CLINICAL RESEARCH
Remote Ischemic Preconditioning Provides Early and Late Protection Against Endothelial Ischemia-Reperfusion Injury in Humans
Role of the Autonomic Nervous System
Stavros P. Loukogeorgakis, BSc*, ,*,
Anna T. Panagiotidou, BSc*,,
Michael W. Broadhead, BSc, MRCP, FRCA ,,
Ann Donald, AVS*,
John E. Deanfield, BA, BChir, MB, FRCP* and
Raymond J. MacAllister, MA, MD, FRCP
* Vascular Physiology Unit, Institute of Child Health, University College London, London, United Kingdom
Portex Anesthesia, Intensive Therapy and Respiratory Medicine Unit, Institute of Child Health, University College London, London, United Kingdom
Centre for Clinical Pharmacology and Therapeutics, University College London, London, United Kingdom
Manuscript received December 7, 2004;
accepted April 13, 2005.
* Reprint requests and correspondence: Mr. Stavros P. Loukogeorgakis, Vascular Physiology Unit, Institute of Child Health, University College London, 34 Great Ormond Street, London, WC1N 3JE, United Kingdom
(Email: s.loukogeorgakis{at}ich.ucl.ac.uk).
OBJECTIVES: The aim of this study was to characterize the time course and neuronal mechanism of remote ischemic preconditioning (RIPC) of the vasculature in humans.
BACKGROUND: Non-lethal ischemia of internal organs induces local (ischemic preconditioning) and systemic (RIPC) resistance to lethal ischemia-reperfusion (IR) injury. Experimental RIPC has two temporal components, is neuronally mediated, is induced by limb ischemia, and reduces infarct size. In humans, RIPC prevents IR-induced vascular injury. Determining the time course and mechanism is a prelude to clinical outcome studies of RIPC.
METHODS: Endothelial IR injury was induced by arm ischemia (20 min) and reperfusion, and measured by flow-mediated dilation. To establish if there are early and late phases, RIPC (three 5-min cycles of ischemia of the contralateral arm) was applied immediately, 4, 24, and 48 h before IR. To determine neuronal involvement, trimetaphan (autonomic ganglion blocker; 1 to 6 mg/min intravenous) was infused during the application of the RIPC stimulus.
RESULTS: Flow-mediated dilation was reduced by IR (8.7 ± 1.1% before IR, 4.9 ± 1.2% after IR; p < 0.001), but not when preceded by RIPC (8.0 ± 0.8% after IR; p = NS); RIPC did not protect after 4 h (4.9 ± 1.1% after IR; p < 0.001), but protected at 24 (8.7 ± 1.1% after IR; p = NS) and 48 h (8.8 ± 1.4% after IR; p = NS). Trimetaphan attenuated early (8.3 ± 1.1% before IR, 4.2 ± 0.9% after IR; p < 0.05) and delayed (7.3 ± 1.0% before IR, 2.3 ± 0.6% after IR, p < 0.001) RIPC.
CONCLUSIONS: Remote ischemic preconditioning in humans has two phases of protection against endothelial IR injury; an early (short) and late (prolonged) phase, both of which are neuronally mediated. The potential for late phase RIPC to provide prolonged protection during clinical IR syndromes merits investigation.
|
Abbreviations and Acronyms
| | FMD = flow-mediated dilation | | GTN = glyceryl trinitrate | | IPC = ischemic preconditioning | | IR = ischemia-reperfusion | | RIPC = remote ischemic preconditioning |
|
This article has been cited by other articles:
|
|
|
|
 
H. L. Lujan and S. E. DiCarlo
Partial Hindlimb Occlusion Reduced the Susceptibility to Sustained Ventricular Tachycardia in Conscious Rats
Journal of Cardiovascular Pharmacology and Therapeutics,
September 1, 2009;
14(3):
199 - 206.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. P. Hoole, P. M. Heck, P. A. White, S. N. Khan, M. O'Sullivan, S. C. Clarke, and D. P. Dutka
Remote Ischemic Preconditioning Stimulus Does Not Reduce Microvascular Resistance or Improve Myocardial Blood Flow in Patients Undergoing Elective Percutaneous Coronary Intervention
Angiology,
August 1, 2009;
60(4):
403 - 411.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Granfeldt, D. J. Lefer, and J. Vinten-Johansen
Protective ischaemia in patients: preconditioning and postconditioning
Cardiovasc Res,
July 15, 2009;
83(2):
234 - 246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Hoole, S. N. Khan, P. A. White, P. M. Heck, R. K. Kharbanda, C. G. Densem, S. C. Clarke, L. M. Shapiro, P. M. Schofield, M. O'Sullivan, et al.
Remote ischaemic pre-conditioning does not attenuate ischaemic left ventricular dysfunction in humans
Eur J Heart Fail,
May 1, 2009;
11(5):
497 - 505.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Valen
Extracardiac approaches to protecting the heart
Eur. J. Cardiothorac. Surg.,
April 1, 2009;
35(4):
651 - 657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Hoole, P. M. Heck, L. Sharples, S. N. Khan, R. Duehmke, C. G. Densem, S. C. Clarke, L. M. Shapiro, P. M. Schofield, M. O'Sullivan, et al.
Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: A Prospective, Randomized Control Trial
Circulation,
February 17, 2009;
119(6):
820 - 827.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Wang, N. Oka, M. Tropak, J. Callahan, J. Lee, G. Wilson, A. Redington, and C. A. Caldarone
Remote ischemic preconditioning elaborates a transferable blood-borne effector that protects mitochondrial structure and function and preserves myocardial performance after neonatal cardioplegic arrest.
J. Thorac. Cardiovasc. Surg.,
August 1, 2008;
136(2):
335 - 342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Hausenloy and D. M. Yellon
Remote ischaemic preconditioning: underlying mechanisms and clinical application
Cardiovasc Res,
August 1, 2008;
79(3):
377 - 386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Webb, N. Patel, S. Loukogeorgakis, M. Okorie, Z. Aboud, S. Misra, R. Rashid, P. Miall, J. Deanfield, N. Benjamin, et al.
Acute Blood Pressure Lowering, Vasoprotective, and Antiplatelet Properties of Dietary Nitrate via Bioconversion to Nitrite
Hypertension,
March 1, 2008;
51(3):
784 - 790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ferdinandy, R. Schulz, and G. F. Baxter
Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning
Pharmacol. Rev.,
December 1, 2007;
59(4):
418 - 458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Walsh, T. Tang, U. Sadat, D. P. Dutka, and M. E. Gaunt
Cardioprotection by remote ischaemic preconditioning
Br. J. Anaesth.,
November 1, 2007;
99(5):
611 - 616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Loukogeorgakis, R. Williams, A. T. Panagiotidou, S. K. Kolvekar, A. Donald, T. J. Cole, D. M. Yellon, J. E. Deanfield, and R. J. MacAllister
Transient Limb Ischemia Induces Remote Preconditioning and Remote Postconditioning in Humans by a KATP Channel Dependent Mechanism
Circulation,
September 18, 2007;
116(12):
1386 - 1395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J Hausenloy and D. M Yellon
The evolving story of "conditioning" to protect against acute myocardial ischaemia-reperfusion injury
Heart,
June 1, 2007;
93(6):
649 - 651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Davidson and M. R. Duchen
Endothelial Mitochondria: Contributing to Vascular Function and Disease
Circ. Res.,
April 27, 2007;
100(8):
1128 - 1141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Schmidt, M. Smerup, I. E. Konstantinov, M. Shimizu, J. Li, M. Cheung, P. A. White, S. B. Kristiansen, K. Sorensen, V. Dzavik, et al.
Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning
Am J Physiol Heart Circ Physiol,
April 1, 2007;
292(4):
H1883 - H1890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E K Iliodromitis, S Kyrzopoulos, I A Paraskevaidis, K G Kolocassides, S Adamopoulos, G Karavolias, and D T Kremastinos
Increased C reactive protein and cardiac enzyme levels after coronary stent implantation. Is there protection by remote ischaemic preconditioning?
Heart,
December 1, 2006;
92(12):
1821 - 1826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Loukogeorgakis, A. T. Panagiotidou, D. M. Yellon, J. E. Deanfield, and R. J. MacAllister
Postconditioning Protects Against Endothelial Ischemia-Reperfusion Injury in the Human Forearm
Circulation,
February 21, 2006;
113(7):
1015 - 1019.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
